Literature DB >> 2877353

Dechloroethylation of ifosfamide and neurotoxicity.

M P Goren, R K Wright, C B Pratt, F E Pell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2877353     DOI： 10.1016/s0140-6736(86)92227-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  38 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.

Authors:  M J Lind; H L Roberts; N Thatcher; J R Idle
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 5.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

6.  Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.

Authors:  Hiroaki Nishimura; Hideki Enokida; Satoshi Nagano; Masahiro Yokouchi; Hiroshi Hayami; Setsuro Komiya; Masayuki Nakagawa
Journal:  J Artif Organs       Date:  2013-10-04       Impact factor: 1.731

7.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

Review 9.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis.

Authors:  Sheron Latcha; Robert G Maki; Gary K Schwartz; Carlos D Flombaum
Journal:  Sarcoma       Date:  2010-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.